Johnson & Johnson COVID-19 Vaccine Granted Authorization under Interim Order by Health Canada For Emergency Use

March 5, 2021 - Johnson & Johnson (the Company) announced today that Health Canada has granted an Interim Order (IO) authorization for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older.This decision was based on scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.Johnson & Johnson anticipates fulfilling the 10 million doses included in the Advance Purchase Agreement with the Government of Canada by the end of Q3 2021.We have been working around the clock to develop and broadly activate our manufacturing capabilities, which will enable us to meet our 2021 supply commitments.The Company will share more information on anticipated delivery timing as it becomes available.“A vaccine that prevents severe disease and protects against COVID-related hospitalization and death will help ease the burden on Canadians and the strain on our healthcare systems,” said Dr. Ebele Ola, Vice President, Medical Affairs, Janssen Canada.“Our single-shot COVID-19 vaccine is a critical tool for fighting this global pandemic.”The terms of the IO allow use of the vaccine while more data are gathered. The Company plans to file for a Notice of Compliance with Healt...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news